Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma

Leukemia and Lymphoma

Volumn 58, Issue 4, 2017, Pages 941-949

  Tiong, Ing S ^a,b   Rodgers, Susan E ^a,c   Lee, Cindy H S ^a,b,d   McRae, Simon J ^a,c,d  

^a Haematology Division   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

hypercoagulability; Monoclonal gammopathy; multiple myeloma; thrombin generation; venous thromboembolism

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BORTEZOMIB; CORTICOSTEROID; ENOXAPARIN; LENALIDOMIDE; POMALIDOMIDE; PROTEIN C; PROTEIN S; THALIDOMIDE; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TRYPSIN INHIBITOR; VON WILLEBRAND FACTOR; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; HEMATOLOGICAL PROCEDURE; HUMAN; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PHENOTYPE; PRIORITY JOURNAL; SIDE EFFECT; THROMBIN GENERATION ASSAY; THROMBIN TIME; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; ADOLESCENT; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; CASE CONTROL STUDY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; THROMBIN; TIME FACTORS; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 85004008121     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428194.2016.1219900     Document Type: Article

References (26)

1. Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112:3582–3586.
2. Kristinsson SY, Pfeiffer RM, Bjorkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma:a population-based study. Blood. 2010;115:4991–4998.
3. Blom JW, Vanderschoot JP, Oostindier MJ, et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients:results of a record linkage study. J Thromb Haemost. 2006;4:529–535.
4. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414–423.
5. Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006;296:2558–2560.
6. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614–1615.
7. De Stefano V, Za T, Rossi E., Venous thromboembolism in multiple myeloma. Semin Thromb Hemost. 2014;40:338–347.
8. Hemker HC, Giesen P, AlDieri R, et al. The calibrated automated thrombogram (CAT):a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002;32:249–253.
9. Baglin T., The measurement and application of thrombin generation. Br J Haematol. 2005;130:653–661.
10. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:4–15.
11. Candelaria D, Armijo B, Montgomery R, et al. Thalidomide increases thrombin generation in multiple myeloma patients. J Clin Oncol. 2006;24:7602.
12. Petropoulou AD, Gerotziafas GT, Zervas K, et al. Kinetics of thrombin generation in patients with multiple myeloma. Blood. 2007;110:3535.
13. Petropoulou AD, Gerotziafas GT, Samama MM, et al. In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide. Thromb Res. 2008;121:493–497.
14. Crowley MP, Kevane B, O'Shea SI, et al. Plasma thrombin generation and sensitivity to activated protein C among patients with myeloma and monoclonal gammopathy of undetermined significance. Clin Appl Thromb Hemost. 2016;22:554–562.
15. Undas A, Zubkiewicz-Usnarska L, Helbig G, et al. Induction therapy alters plasma fibrin clot properties in multiple myeloma patients:association with thromboembolic complications. Blood Coagul Fibrinolysis. 2015;26:621–627.
16. Rodgers SE, Wong A, Gopal RD, et al. Evaluation of pre-analytical variables in a commercial thrombin generation assay. Thromb Res. 2014;134:160–164.
17. Crowley MP, Quinn S, Coleman E, et al. Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma. J Thromb Thrombolysis. 2015;39:245–249.
18. Kyle RA, Rajkumar SV., Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3–9.
19. Kraaijenhagen RA, in't Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost. 2000;83:5–9.
20. Gracheva MA, Urnova ES, Sinauridze EI, et al. Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma. Leuk Lymphoma. 2015;56:3418–3425.
21. Elice F, Fink L, Tricot G, et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol. 2006;134:399–405.
22. Robak M, Trelinski J, Chojnowski K., Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma. Med Oncol. 2012;29:3574–3580.
23. Kovacs MJ, Davies GA, Chapman JA, et al. Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma:effect on thrombin generation and procoagulant markers in NCIC CTG MY.10. Br J Haematol. 2015;168:511–517.
24. Abdullah WZ, Roshan TM, Hussin A, et al. Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin. Blood Coagul Fibrinolysis. 2013;24:893–895.
25. Ay C, Dunkler D, Simanek R, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation:results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2011;29:2099–2103.
26. Dargaud Y, Luddington R, Gray E, et al. Effect of standardization and normalization on imprecision of calibrated automated thrombography:an international multicentre study. Br J Haematol. 2007;139:303–309.